Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials

(2015) Mukul Minocha et al.   CLINICAL PHARMACOKINETICS

Immunological differences between classical phenothypes of multiple sclerosis

(2015) Piotr Iwanowski et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

(2014) Ahmed A. Othman et al.   CLINICAL PHARMACOKINETICS

Daclizumab (anti-CD25) in multiple sclerosis

(2014) Nikolai Pfender et al.   EXPERIMENTAL NEUROLOGY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

(2014) Gavin Giovannoni et al.   LANCET NEUROLOGY

Emerging injectable therapies for multiple sclerosis

(2013) Jiwon Oh et al.   LANCET NEUROLOGY

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology